160 related articles for article (PubMed ID: 8723444)
21. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
[TBL] [Abstract][Full Text] [Related]
22. The effect of viral inoculum level and host age on disease incidence, disease severity, and mortality in a murine model of ocular HSV-1 infection.
Kintner RL; Brandt CR
Curr Eye Res; 1995 Feb; 14(2):145-52. PubMed ID: 7768106
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of cobalt chelates in the rabbit eye model for epithelial herpetic keratitis.
Asbell PA; Epstein SP; Wallace JA; Epstein D; Stewart CC; Burger RM
Cornea; 1998 Sep; 17(5):550-7. PubMed ID: 9756451
[TBL] [Abstract][Full Text] [Related]
24. Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice.
Smith TJ; Ackland-Berglund CE; Leib DA
J Virol; 2000 Apr; 74(8):3598-604. PubMed ID: 10729135
[TBL] [Abstract][Full Text] [Related]
25. A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing.
Brandt CR; Coakley LM; Grau DR
J Virol Methods; 1992 Mar; 36(3):209-22. PubMed ID: 1560105
[TBL] [Abstract][Full Text] [Related]
26. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.
Anand BS; Hill JM; Dey S; Maruyama K; Bhattacharjee PS; Myles ME; Nashed YE; Mitra AK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2529-34. PubMed ID: 12766053
[TBL] [Abstract][Full Text] [Related]
27. Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.
Berdugo M; Larsen IV; Abadie C; Deloche C; Kowalczuk L; Touchard E; Dubielzig R; Brandt CR; Behar-Cohen F; Combette JM
Antimicrob Agents Chemother; 2012 Mar; 56(3):1390-402. PubMed ID: 22203590
[TBL] [Abstract][Full Text] [Related]
28. Development of Herpes Simplex Virus Infectious Epithelial Keratitis During Oral Acyclovir Therapy and Response to Topical Antivirals.
Carter SB; Cohen EJ
Cornea; 2016 May; 35(5):692-5. PubMed ID: 26989961
[TBL] [Abstract][Full Text] [Related]
29. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.
Loutsch JM; Sainz B; Marquart ME; Zheng X; Kesavan P; Higaki S; Hill JM; Tal-Singer R
Antimicrob Agents Chemother; 2001 Jul; 45(7):2044-53. PubMed ID: 11408221
[TBL] [Abstract][Full Text] [Related]
30. Application of FGF-2 to modulate herpetic stromal keratitis.
Kim B; Lee S; Kaistha SD; Rouse BT
Curr Eye Res; 2006 Dec; 31(12):1021-8. PubMed ID: 17169840
[TBL] [Abstract][Full Text] [Related]
31. Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group.
Cornea; 2001 Mar; 20(2):123-8. PubMed ID: 11248812
[TBL] [Abstract][Full Text] [Related]
32. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
33. Tetrandrine potently inhibits herpes simplex virus type-1-induced keratitis in BALB/c mice.
Hu S; Dutt J; Zhao T; Foster CS
Ocul Immunol Inflamm; 1997 Sep; 5(3):173-80. PubMed ID: 9326762
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
35. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
[TBL] [Abstract][Full Text] [Related]
36. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea.
Fujihara T; Hayashi K
Arch Virol; 1995; 140(8):1469-72. PubMed ID: 7661698
[TBL] [Abstract][Full Text] [Related]
37. Topical use of rapamycin in herpetic stromal keratitis.
Zapata G; Racca L; Tau J; Berra A
Ocul Immunol Inflamm; 2012 Oct; 20(5):354-9. PubMed ID: 23030354
[TBL] [Abstract][Full Text] [Related]
38. Effect of aminoguanidine, a nitric oxide synthase inhibitor, on ocular infection with herpes simplex virus in Balb/c mice.
Benencia F; Courrèges MC; Gamba G; Cavalieri H; Massouh EJ
Invest Ophthalmol Vis Sci; 2001 May; 42(6):1277-84. PubMed ID: 11328740
[TBL] [Abstract][Full Text] [Related]
39. A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.
Jose GG; Larsen IV; Gauger J; Carballo E; Stern R; Brummel R; Brandt CR
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1070-9. PubMed ID: 23341013
[TBL] [Abstract][Full Text] [Related]
40. PCR assessment of HSV-1 corneal infection in animals treated with rose bengal and lissamine green B.
Stroop WG; Chen TM; Chodosh J; Kienzle TE; Stroop JL; Ling JY; Miles DA
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2096-102. PubMed ID: 10892849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
